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                                                           introduction
               Neuropsychiatric systemic lupus erythematosus (NPSLE) could be defined as the neurologic 
syndromes of the central, peripheral and autonomic nervous system and the psychiatric syndromes 
observed in patients with SLE in which other causes have been excluded. 
Hebra and Kaposi in 1875[1] were the first to note central nervous involvement in lupus and 
while writing on the erythema group of skin diseases in 1885, Osler[2] discussed cerebral changes in 
SLE and reported a patient with SLE and hemiplegia. 
Since the first description of SLE in the nineteenth century by Kaposi and Osler, it soon became 
obvious that the plethora of NPSLE manifestations were not easy to handle in a uniform and 
reproducible way. Symptoms and signs could be focal, diffuse, central, peripheral, psychiatric, isolated, 
complex, simultaneous and sequential, representing both active and inactive disease states. Attribution 
of any manifestations to SLE, whether it be to make a clinical diagnosis or to study the condition, is a 
problem since concomitant drugs, infections, metabolic disorders or atherosclerotic disease can cause 
neuropsychiatric manifestations and make it extremely difficult to separate these from genuine lupus 
manifestations. Kassan and Lockshin were one of the first to draw attention to the complexity of 
nervous system manifestations of SLE and the need for a more organized and more easily translatable 
classification. In addition to recognizing specific manifestations, they stressed the importance of 
confounding variables and assessing the chronological course and functional impact of NP events. 
How et al. developed a classification of NP-SLE for their studies of antineuronal antibodies. They 
identified major and minor neurologic and psychiatric manifestations. An individual patient was 
deemed to have NP-SLE if they had one major criterion alone or one minor criterion plus an 
abnormality on electroencephalography, nuclear brain scanning, cerebrospinal fluid (CSF) examination 
or cerebral angiography. Other potential etiologic features such as uremia, hypertension, infection and 
corticosteroids were considered and excluded prior to attributing the NP event to SLE. However, non-
SLE controls were not included in the study and this classification scheme for NP-SLE remains 
unvalidated. 
Potential involvement of the nervous system by systemic lupus erythematosus (SLE) has been 
recognized ever since the multisystem nature of the disease first was appreciated. Clinical features 
include both neurologic (N) and psychiatric (P) manifestations, which may involve both the central and 
peripheral nervous systems. Although there have been significant advances in understanding some 
aspects of neuropsychiatric (NP) SLE in recent years, nervous system disease continues to pose 
diagnostic, therapeutic, and scientific challenges for physicians and researchers alike. 
Classification of neuropsychiatric systemic lupus erythematosus
It is generally  accepted that the NP manifestations of SLE include a much broader spectrum of disease 
than the two features included in the current American College of Rheumatology (ACR) classification 
criteria [3,4], namely seizures and psychosis. Central nervous system (CNS) involvement predominates 
over peripheral nervous system disease and may take the form of diffuse disease (e.g., psychosis and 
depression) or focal disease (e.g., stroke and transverse myelitis) depend upon the anatomic location of 
pathology. Over time, several classifications have been developed for NP-SLE [5–7], none of which 
has received universal acceptance. A deficiency in many of the classifications of NP-SLE has been the 
lack of definition of individual manifestations and lack of standardization for investigation and 
diagnosis.
In 1999, the ACR research committee produced a standard nomenclature and set of case definitions for 
NP-SLE [8]. Using a consensus approach and drawing on a pool of experts from several subspecialties 
including rheumatology, neurology, immunology, psychiatry, and neuropsychology, 19 NP syndromes 
(Box 1) were defined, and diagnostic criteria were developed [8]. For each NP syndrome, potential 
etiologies other than SLE were identified for either exclusion, or recognition as an association, 
acknowledging that in some clinical presentations it is not possible to be definitive about attribution. 
The issue of the identification of other potential causes for NP events in SLE patients is critical and was 
not addressed adequately in previous studies of NP-SLE.
Box: 1 Neuropsychiatric syndromes in systemic lupus erythematosus 
as defined by the American College of Rheumatology: 
Central nervous system:
Aseptic meningitis 
Cerebrovascular disease 
Demyelinating syndrome 
Headache 
Movement disorder 
Myelopathy 
Seizure disorders 
Acute confusional state 
Anxiety disorder 
Cognitive dysfunction 
Mood disorder 
Psychosis
Peripheral nervous system
Guillain-Barre syndrome 
Autonomic neuropathy 
Mononeuropathy 
Myasthenia gravis 
Cranial neuropathy 
Plexopathy 
Polyneuropathy
Epidemiology
The ACR nomenclature and case definitions for NP-SLE have been validated in a cross-sectional, 
population-based study by Ainiala et al [9]. Forty-six SLE patients were compared with 46 individuals 
randomly selected from the Finnish population register and matched by age, gender, education, and 
residence. At least one NP manifestation was identified in 91% of the 46 Finnish patients compared 
with 54% of controls. This provided an odds ratio of 9.5 (95% confidence interval (CI) 2.21 to 40.8) for 
the occurrence of an NP event and specificity of 46%. 
By excluding headache, anxiety, mild depression, mild cognitive impairment, and polyneuropathy 
without electrophysiological confirmation, the prevalence of NP disease fell from 91% to 46% in SLE 
patients and from 54% to 7% in controls. This provided an odds ratio of 7.0 (95% CI 2.09 to 23.47) and 
specificity of 93%. In addition to the study of Ainiala et al, at least four other groups [10–13] have used 
the ACR nomenclature to classify their SLE cohorts for NP-SLE manifestations. 
The overall prevalence of NP disease in these patient populations has varied between 37% and 95%.Of 
interest, the range in the prevalence of NP-SLE in these studies was as wide as that reported before the 
introduction of the ACR nomenclature. In previous studies, NP disease was reported in 14% to 75% of 
SLE patients [14–16]. The attribution of individual NP events to SLE or to an alternative etiology 
remains a challenge. In the absence of a diagnostic gold standard for most of the NP-SLE syndromes, 
attribution is determined on the basis of exclusion using the best available clinical, laboratory, and imaging 
data. 
The ACR nomenclature [8] provide a basis for addressing this issue in a systematic manner, because 
for each NP syndrome there is a comprehensive list of exclusions and associations, the presence of 
which may indicate an alternative etiology. Using this approach and taking into consideration the 
temporal relationship between the NP event and the diagnosis of SLE, a recent study has determined 
that up to 41% of all NP events in SLE patients may be attributed to factors other than lupus. 
[11]Despite the improved definitions for individual NP syndromes, there continues to be substantial 
variability in the overall prevalence of NP disease between different populations. Whether this 
represents inherent differences between study cohorts or a bias in data acquisition remains to be 
determined. None of the individual NP manifestations are unique to lupus, and indeed some occur with 
considerable frequency in the general population. 
Thus, the inclusion of control groups is critical to determine whether the prevalence of NP disease in 
SLE patients is in excess of that found in the normal population and in other chronic disease groups. 
Because many of the NP syndromes are quite rare (less than 1%), multicenter efforts will be required to 
assemble sufficient numbers of patients for study. Attribution of NP disease in individual patients 
remains a challenge, particularly in the absence of a diagnostic gold standard. Nevertheless, current 
evidence suggests that non-SLE factors likely contribute to a substantial proportion of NP disease in 
SLE patients, particularly the softer NP manifestations such as headache, anxiety, and some mood 
disorders. 
Etiology of neuropsychiatric systemic lupus erythematosus
Given the plethora of NP manifestations reported in SLE patients, it is unlikely that there is a single 
pathogenic mechanism. NP events in SLE may be caused by a primary manifestation of the disease, 
secondary complications of the disease or therapy such as hypertension or infection, or a coincidental 
problem unrelated to lupus (Fig. 1).
Fig 1 Contributing factors                     Primary NP-SLE 
Vasculopathy +++ + 
Autoantibodies 
Antineuronal – +  
Antiribosomal – ++
Antiphospholipid +++ + 
Inflammatory mediators +   ++
Focal NP Disease Diffuse NP Disease 
                                            Sec.NP-SLE   Concurrent non-SLE NP disease                         
Complications of SLE therapy (e.g. steroids, infection)
           Complications of SLE (e.g.uremia, hypertension) 
Box 2. Pathogenesis of neuropsychiatric systemic lupus 
erythematosus
Vascular abnormalities
Noninflammatory vasculopathy 
Vasculitis 
Thrombosis
Auto antibodies
Anti neuronal antibodies 
Antiribosomal P antibodies 
Antiphospholipid antibodies
Inflammatory mediators
IL-2, 6, 8, and 10 
Interferon-alpha 
Tumor necrosis factor–alpha 
Matrix metalloproteinase (MMP)–9
Vasculopathy
Evidence in support of vascular abnormalities in NP-SLE may be found in neuropathologic studies 
[17–18]. A bland, noninflammatory vasculopathy involving small vessels was the predominant finding 
in these studies. In contrast, inflammatory disease of small or large vessels was rare. Brain micro 
infarcts occurred in association with, and were attributed to the microangiopathy [17]. Although 
instructive, there are significant limitations to using brain pathology as a means of advancing 
understanding of NP-SLE. First, patients who come to autopsy, which has been the most frequent 
source of brain tissue, represent a subset of patients with the most severe disease. Second, there is 
frequently a temporal disconnect between the NP event and tissue sampling. Third, this approach is 
restricted to the detection of structural abnormalities. Finally, confounding factors such as infection, 
hypertension, or corticosteroids may modify the original pathology that occurs as a consequence of the 
disease. The solution to these problems may come from advances in imaging technology that can act 
as a surrogate for brain biopsy.
Auto antibodies
A humoral immune response directed against several families of auto antigens on neurons, ribosomes, 
and phospholipid-associated proteins has been implicated to a varying extent in the pathogenesis of 
NP-SLE. The data from human studies implicating antineuronal antibodies is largely circumstantial. 
This includes the temporal relationship between clinical events and serologic findings [19], the 
presence of auto antibodies in the cerebrospinal fluid (CSF) [20], and, to a very limited extent, their 
identification in neuronal tissues from patients succumbing to the disease [21]. The presence of auto 
antibodies in the CSF of SLE patients is likely because of passive transfer from the circulation through 
a permeabilized blood–brain barrier [22,23], and, independently, to direct intrathecal production 
[19,22]. 
More direct evidence for the pathogenic potential of antineuronal antibodies is derived from animal 
studies in which the intracranial injection of auto antibodies reactive with neuronal tissues has been 
shown to induce memory deficits, seizures, and neuropathologic changes. Considerable effort has gone 
into identifying the fine specificity of this family of auto antibodies. For example, Hanson et al [24] 
described reactivity to a 50-kd neuronal membrane protein in SLE patients. These auto antibodies 
bound to the surface of cultured rat neuroblastoma cells, and on Western blotting identified a protein of 
comparable size in human fetal brain and bovine adult brain. Although there was a significant 
association between these auto antibodies and NP-SLE, this was not restricted to any particular clinical 
subset of NP disease. 
Auto-antibodies to gangliosides, which are a family of acid glycolipids predominantly located on 
neuronal and myelin membranes in the central and peripheral nervous system, have been studied 
extensively in SLE and in neurologic disorders such as multiple sclerosis. Although present in serum 
and CSF of SLE patients, there has not been a consistent association with NP manifestations of the 
disease. 
Anti-lymphocyte antibodies are not specific for SLE and can occur in other illnesses, including 
infections, malignancy, inflammatory bowel disease, and multiple sclerosis. A subset of 
antilymphocyte antibodies, however, cross-react with neurons. Fever, neuropsychiatric symptoms, skin 
lesions, and hematologic abnormalities are the most common manifestations in patients with SLE and 
serum lymphocytotoxic antibodies. Denburg et al. has related cognitive dysfunction to the presence of 
serum IgM lymphocytotoxic antibodies in over 445 patients evaluated. This may reflect the presence of 
the antineuronal subset of antilymphocyte antibodies.
Most recently, attention has been focused on anti-NR2 glutamate receptor antibodies as a potentially 
novel system that could explain some of the complexities of NP-SLE. The NMDA (N-methyl-d-
aspartate) receptors NR2a and NR2b bind the neurotransmitter glutamate and are present on neurons 
throughout the forebrain [25]. The hippocampus, which is the anatomical structure closely linked to 
learning and memory, has the highest density of brain NMDA receptors. In addition to their putative 
role in learning and memory [26], these receptors display altered expression in major psychoses, and if 
engaged by receptor antagonists, they cause hallucinations and paranoia.                                     
A recent study [27] has shown that a subset of anti-DNA antibodies, derived from both murine models 
of SLE and from four human subjects with the disease, cross-react with a pentapeptide consensus 
sequence that is present in the extracellular, ligand binding domain of NR2 receptors. Moreover, these 
antibodies induced apoptotic cell death of neurons in vitro and in vivo and were present in the CSF of 
one SLE patient with progressive cognitive decline. 
Thus, in contrast to the previously described antineuronal antibodies in SLE, the anti-NR2 glutamate 
receptor antibodies appear to have a functional consequence leading to neuronal injury in a manner 
similar to that seen in excitatory amino acid toxicity. In this model, excessive stimulation of the 
receptor is followed by increased entry of calcium into the cell and subsequent cell death. Although of 
interest in elucidating a novel pathway for neuronal injury in SLE, these findings are preliminary, 
largely derived from animal studies, and require confirmation in human subjects with NP-SLE.    
Antiribosomal (anti-P) antibodies first were described in SLE patients in 1985 and are quite specific for 
SLE, with a prevalence of 13% to 20% depending upon the ethnic group [28]. In 1987, these auto 
antibodies were linked to NP-SLE, in particular psychosis [29]. Subsequent work has either supported, 
refuted, or extended this initial observation to include depression [30, 31]. Potential explanations for 
the differences is study outcomes include different diagnostic criteria for psychiatric disease, variance 
in the temporal relationship between clinical events and serologic testing, and differences in assay 
technique, particularly antigen preparation and purity. 
One of the largest studies [30] examined 394 SLE patients, 63 (16%) of whom had anti-P antibodies. 
There was a significant association with psychosis and depression, with odds ratios between 4 and 10. 
Because of the low prevalence of clinical events, however, the positive predictive value was only 13% 
and 16% for psychosis and depression, respectively. This has important implications for the application 
of this serologic test in decision-making for individual patients. In contrast, a more recent study of 149 
patients [31], 12% of whom had anti-P antibodies, did not find an association with any of the NP 
syndromes as defined by the ACR nomenclature [8]. Additional observations on anti-P antibodies are 
of interest and may provide insight into their pathogenic mechanisms.  
In a study of 87 SLE patients, Isshi et al [32] found a significant elevation in circulating anti-P 
antibodies in 34 patients who had lupus psychosis, but there was no increase in the level of serum 
antineuronal antibodies. In contrast, examination of the CSF from the same patients revealed a 
significant elevation in antineuronal antibodies but not in anti-P antibody levels. These data suggest 
potential interaction between these two families of auto antibodies in the pathogenesis of NP-SLE. 
Autoimmune antiphospholipid antibodies, which are directed against phospholipid-binding proteins 
such as beta 2 -glycoprotein I and prothrombin, are associated with predominately focal 
manifestations of NP-SLE. 
The most common neurologic disorders are those of vascular origin such as transient cerebral ischemia 
or stroke, but other associations include seizures, chorea, transverse myelitis, and cognitive 
dysfunction. In a review of over 1000 SLE patients, Love and Santoro reported neuropsychiatric 
manifestations in 38% of patients who had lupus anticoagulant compared with 21% of patients who did 
not have these antiphospholipid antibodies [33]. The favored pathogenic mechanism for this subset of 
auto antibodies in NP-SLE is thrombosis within vessels of different caliber and subsequent cerebral 
ischemia. A procoagulant state may be induced through acquired resistance to protein C and protein S, 
platelet aggregation, and direct activation of endothelial cells.  However, the intrathecal production of 
antiphospholipid antibodies in NP-SLE patients [22], their association with diffuse cognitive 
impairment [34], and in vitro evidence indicating modulation of neuronal cell function raise the 
possibility of an alternative pathogenic mechanism.
Inflammatory mediators
The potential role of proinflammatory cytokines in neuropsychiatric lupus has received increasing 
attention in recent years. Studies in Japan were the first to report an association between enhanced 
intracranial production of interleukin (IL-6) with seizures [35] and interferon alpha with lupus 
psychosis [36]. Subsequent studies have provided further evidence for the intrathecal production of 
IL-6 [37, 38] and have identified other potential candidate cytokines such as IL-10 [39], IL-2 [40], IL-8 
and tumor necrosis factor alpha [38]. Potential sources for the intrathecal production of these cytokines 
include neuronal and glial cells [36, 37].
Other potentially important inflammatory mediators are MMPs, a family of endoperoxidases that can 
degrade extracellular matrix components. MMP-9 is a gelatinase and is secreted by a variety of cells in 
the vessel wall, including macrophages, T lymphocytes, and endothelial and smooth muscle cells. 
Implicated in the pathogenesis of plaque rupture, elevated levels also have been associated with other 
conditions, including multiple sclerosis, Guillain-Barre syndrome, rheumatoid arthritis, and SLE. A 
recent study [40] examined the association between circulating levels of MMP-9 and NP-SLE. 
Although there was no difference in the levels of MMP-9 between SLE patients and healthy population 
controls, elevated levels of MMP-9 were associated with NP-SLE, and in particular with cognitive 
impairment. There was a positive correlation between circulating MMP-9 levels and both T1 and T2 
lesions on brain MRI. It is also of interest that increased expression of MMP-9 is found in the disrupted 
blood–brain barrier following cerebral ischemia and may facilitate lymphocyte migration into and 
possibly through the arterial wall [41].
 As with other organ involvement in SLE, nervous system disease may occur at any time in the disease 
course. Nevertheless, it is of interest that NP-SLE frequently presents early in the disease course, either 
before or following the diagnosis of lupus [42]. NP events in patients who have active multiorgan 
disease from lupus is well recognized [17], and when it occurs, it provides support for the notion that 
lupus is the most likely cause of the NP manifestation. NP-SLE, however, may also occur in the setting 
of globally quiescent lupus.
Cognitive dysfunction, assessed using neuropsychologic assessment techniques, has been reported in 
up to 80% of SLE patients. These tests evaluate the functional integrity of the CNS through systematic 
assessment of performance on specific tasks. The tests are administered and scored in a standardized 
manner and assess multiple areas of cognitive function, including simple and complex attention, 
memory, visual–spatial processing, language, reasoning, psychomotor speed, and executive functions. 
Results can be expressed in relation to normative data or in terms of the estimated premorbid level of 
function or competence. 
As most SLE patients who have cognitive impairment have relatively mild deficits, the careful 
selection and assessment of cognitive performance in control groups is of critical importance to define 
expected levels of function in healthy individuals and those with other chronic diseases. Although 
cognitive impairment may be viewed as a distinct subset of NP-SLE, it also can serve as a surrogate of 
overall brain health in SLE patients, which may be affected by several factors including other NP 
syndromes. The range in prevalence of cognitive impairment in SLE [14, 43] is most likely because of 
differences in selection of patients for study and lack of uniform definitions for cognitive impairment. 
There is no specific or unique pattern of cognitive impairment in SLE, and many individual patients 
have subclinical deficits.  
Clinical impact and prognosis of neuropsychiatric systemic lupus erythematosus
The clinical impact of NP events in SLE has been determined by examining the association with 
several clinical indicators including quality of life. The NP events in SLE patients, regardless of their 
etiology and attribution, have a negative impact on quality of life. Although the overall clinical impact 
of NP-SLE may be detrimental, it is likely that individual NP manifestations differ in their prognostic 
implications. For example, the subtle cognitive deficits detected by formal neuropsychologic testing 
have not been associated with a negative impact on quality of life, at least as determined by self-report 
questionnaires. 
Diagnostic imaging and neuropsychiatric systemic lupus erythematosus
When considering neuroimaging in NP-SLE it is helpful to incorporate an assessment of brain structure 
and brain function. Although CT scanning is the preferred technique for the diagnosis of acute 
intracranial hemorrhage, it largely has been replaced by MRI for detecting other abnormalities because 
of its increased sensitivity. Abnormalities on MRI scanning may be found in 19% [51] to 70% [52] of 
SLE patients. T2weighted MRI images identify pathologic processes that cause edema and are more 
sensitive than T1 -weighted images for detecting abnormalities in NP-SLE patients. 
Applying the technique of fluid-attenuating inversion recovery (FLAIR), to dampen the CSF signal and 
highlight areas of edema, further enhances the utility of T2-weighted images [53]. Focal neurologic 
disease is associated with predominately fixed lesions in the periventricular and subcortical white 
matter usually in the territory of a major cerebral blood vessel. These multiple white matter lesions are 
quite nonspecific, however, and more commonly are attributed to hypertension, disease duration, and 
age-related small vessel disease than to the presence of NP-SLE [54]. If the lesions are larger, occur in 
the corpus collosum, and are seen on T1 -weighted images, then the diagnosis of multiple sclerosis has 
to be considered. 
Diffuse NP clinical presentations are associated with transient subcortical white matter lesions and 
patchy hyper intensities in the gray matter that usually are not confined to the territories of major 
cerebral blood flow. Other abnormalities detected on MRI scanning in SLE patients include cerebral 
infarction, venous sinus thrombosis, and increased signal in the spinal cord accompanying the clinical 
presentation of myelopathy. MRI also provides quantitative volumetric analysis of brain atrophy. 
The most objective neuroimaging study of brain function is positron emission tomography (PET) 
scanning, but practical considerations limit its applicability. Single photon emission computed 
tomography (SPECT) scanning often is regarded as the poor man’s PET [55]. This provides semi 
quantitative analysis of regional cerebral blood flow and metabolism. It is exquisitely sensitive, and in 
studies of SLE patients [56, 57], SPECT imaging has identified diffuse and focal deficits that may be 
fixed or reversible. The findings are not specific for SLE, however, and do not always correlate with 
clinical NP manifestations. 
The interpretation of what these imaging abnormalities indicate is not always clear. The most common 
explanation is that they reflect a primary or secondary reduction in blood flow. In the brain, however, 
there is sometimes disassociation between metabolism and blood flow. Changes in blood flow and 
metabolism can occur in sites distant from those of the pathologic lesion, a phenomenon known as 
diaschisis. A study [58] of concurrent SPECT and PET imaging in 25 SLE patients, 13 of whom had a 
history of NP-SLE, indicated the superiority of PET scanning. 
Furthermore, the abnormalities in glucose metabolism detected by PET scanning are reversible with the 
institution of antiinflammatory and immunosuppressive therapies [59] but may also progress to 
structural changes within the brain as detected by subsequent MRI.The application of several 
technologies to MRI scanning has provided additional opportunities to assess brain metabolism and 
function. 
Magnetic resonance angiography (MRA) permits a noninvasive visualization of cerebral blood flow, 
although it is probably not optimal for visualization of flow in small caliber vessels, which are the ones 
primarily involved in NP-SLE. Magnetic resonance spectroscopy (MRS) allows the identification and 
quantification of brain metabolites, thereby providing indirect evidence of cellular changes. Thus, the 
amount of N-acetyl (NA) compounds, which reflect the quantity and integrity of neuronal cells, is 
reduced in lupus brains. 
Studies of SLE patients have found an association between reduced NA brain levels with 
neurocognitive dysfunction [60] and independently with elevated IgG antiphospholipid antibodies [61]. 
Brain lactate levels also are elevated, indicating ischemia and inflammation, while choline compounds 
are increased, reflecting damaged cell membranes and myelin destruction. 
Magnetization transfer imaging (MTI) is particularly suited to the detection and quantification of 
diffuse brain damage. This technique quantifies the exchange of protons between water within a 
macromolecule such as myelin and protons in free water. Either the loss of myelin or the accumulation 
of edema will alter the transfer, which is expressed as the magnetization transfer ratio (MTR) [62]. 
Studies have revealed a lower MTR in patients who have NP-SLE and multiple sclerosis, while there 
was no difference between healthy controls and SLE patients who did not have NP disease [52, 63]. 
The findings in SLE patients correlated with the results of cognitive assessment and psychiatric 
functioning. As both MRS and MTI identified abnormalities in SLE patients who have normal MRI 
scans, these techniques provide a means for detecting and quantifying brain injury in NP-SLE patients 
that is not apparent with other imaging modalities. 
Diffusion weighted imaging (DWI) is highly effective for detecting hyperacute brain injury, in 
particular acute ischemia following stroke when the diffusion of water is highly restricted because of 
the acute shift of fluid into the intracellular compartment and cytotoxic edema [62]. Such abnormalities 
are not seen in multiple sclerosis. In a study of 20 SLE patients by Moritani et al [64], DWI 
abnormalities were detected in four cases. Functional MRI measures cerebral blood flow and neuronal 
activity by measuring oxygenation status of hemoglobin, and studies of SLE patients using this 
technique are awaited with interest. Although none of these techniques identify abnormalities that are 
unique to NP-SLE patients it will be of considerable interest to examine their clinical significance and 
evolution over time and to determine the potential for reversibility.  
BIOLOGIC MARKERS OF NERVOUS SYSTEM DAMAGE
Nonspecific abnormalities may be found in the CSF of 33% of patients who have NP disease [65]. 
They include pleocytosis and elevated protein levels.  The elevated levels of CSF neurofilament triplet 
protein (NFL), which reflects neuronal and in particular axonal damage, were increased in SLE patients 
who have NP-SLE compared with SLE patients who do not have NP disease and healthy controls (66). 
The sensitivity was 74% and specificity 65%. Likewise, the level of CSF glial fibrillary acidic protein 
(GFAP), which indicates astrogliosis or scarring, was increased in the same patient population, with a 
sensitivity of 48% and specificity of 87%. 
Moreover, the levels of both NFL and GFAP were associated with abnormalities on MRI scanning and 
were reduced following the successful treatment of several NP manifestations with cyclophosphamide. 
Although elevated levels of NFL and GFAP are not restricted to SLE, these data indicate a potentially 
objective, biologic indicator of nervous system disease in lupus patients.
Diagnosis and management of neuropsychiatric systemic lupus erythematosus
The first step in the management of a patient with SLE who presents with a NP event is to determine 
whether the event can be convincingly attributed to SLE, a complication of the disease or its therapy, or 
whether it reflects a coincidental disease process. This is achieved largely by a process of exclusion, 
given the absence of a diagnostic gold standard for most of the NP manifestations that occur in SLE. 
Thus, the correct diagnosis is derived from a careful analysis of the clinical, laboratory, and imaging 
data on a case-by-case basis. The spectrum of diagnostic tests available is listed in Box 3, and these 
may be used to a varying extent depending upon the clinical circumstances.
Examination of the CSF should be considered primarily to exclude infection. Analysis of CSF 
autoantibodies, cytokines, and biomarkers of neurologic damage is still in the research arena. In 
considering autoantibodies, those that are most likely to provide the greatest diagnostic yield are 
antiphospholipid antibodies. The value of measuring anti-P antibodies remains uncertain given the 
conflicting results to date, while the role of anti-NR2 antibodies in NP-SLE is unknown. 
Neuroimaging should include a modality to assess brain structure and another to assess brain function. 
Neuropsychologic testing only should be done to address specific concerns about cognitive ability, as 
the detection of isolated subclinical deficits appears to have little clinical significance. 
The spectrum of investigations in the assessment of systemic lupus erythematosus patients for 
neuropsychiatric disease is listed in (BOX 3) Management will need to be tailored according to the 
individual patient’s needs (Box 4), and there remains a paucity of controlled studies to guide treatment 
decisions. Once a diagnosis of NP-SLE is established, the first step is to identify and treat potential 
aggravating factors such as hypertension, infection, and metabolic abnormalities.
BOX 3 INVESTIGATIONS
Cerebrospinal fluid 
Exclude infection  
Autoantibodies
Cytokines  
Autoantibodies  
Antiphospholipid 
Antineuronal 
Antiribosomal P 
Neuroimaging 
Brain structure (CT, MRI) 
           Brain function (PET, SPECT, MRI, MRA, MRS, MTI, DWI, FMRI)    Neuropsychologic 
assessment
                     Symptomatic therapy with, for example, anti- convulsants, antidepressants, and 
antipsychotic medications, should be considered if appropriate. Immunosuppressive therapy with high 
dose corticosteroids, cyclophosphamide, and azathioprine has been used to treat many NP-SLE 
manifestations. With the exception of one study [67], there are no placebo- controlled studies 
examining the benefit of oral or intravenous corticosteroids in NP lupus. Similarly, pulse intravenous 
cyclophosphamide therapy [68-70], akin to that which has been used in the treatment of lupus nephritis, 
has been reported to be beneficial in NP-SLE, although no controlled studies have been performed. A 
recent open-label study of 13 patients who had lupus psychosis reported a favorable outcome in all 
patients treated with oral cyclophosphamide for 6 months followed by maintenance therapy with 
azathioprine [71]. In virtually all of these studies, immunosuppressive therapy has been used in conjunction 
with corticosteroids in addition to symptomatic therapies, such as antipsychotic medications. 
BOX 4 MANAGEMENT
Establish diagnosis of NP-SLE
Identify aggravating factors 
Hypertension 
Infection  
Metabolic abnormalities 
Symptomatic therapy  
Anticonvulsants  
Psychotropics  
Anxiolytics 
Immunosuppression  
Corticosteroids  
Azathioprine  
Cyclophosphamide 
B-lymphocyte depletion 
Anticoagulation  
Heparin  
Warfarin
More targeted immunosuppressive therapies, for example B lymphocyte depletion with anti-CD20 used 
alone or in combination with   cyclophosphamide [72], is promising but requires further study. 
Anticoagulation is indicated strongly for focal disease when antiphospholipid antibodies are implicated, 
and such therapy usually will be lifelong [73]. There are several opportunities for novel or improved 
therapies in the future. The optimal management of intracranial thrombosis should become clearer 
following the completion of controlled studies of anticoagulation therapy in patients who have primary 
antiphospholipid antibody syndrome, although studies to date have yielded conflicting results. 
Due to the lack of controlled randomized trials there is a desperate need to assess the efficacy of 
various therapeutic interventions in CNS lupus, where the treatment is still empirical and based on 
clinical experience. Before deciding to treat and how to treat, the major points that need to be 
considered are: i) accurate diagnosis; ii) identification and treatment of contributing causes of CNS 
disease; iii) assessment of the severity; and iv) identification of the probable underlying pathogenic 
mechanism(s). 
In this context, a better approach to management of CNS lupus may be achieved by: i) the recognition 
of the APS (a common thrombotic disease) and its treatment with anticoagulants; ii) a more 
conservative use of steroids, especially in patients with mild manifestations; and iii) the use of pulse 
cyclophosphamide in diffuse/nonthrombotic CNS lupus. Patients with mild manifestations (e.g., 
headache or depression) may need symptomatic treatment only, with analgesics, antidepressants and 
psychological support. In more severe CNS manifestations it is vitally important to distinguish between 
thrombotic and nonthrombotic mechanisms. 
Focal CNS manifestations, generally due to an underlying thrombotic mechanism, are more often 
associated with the presence of aPL, and long-term anticoagulation is the therapeutic choice in these 
cases. Heparin is indicated during the acute phase, followed by long-term warfarin in order to prevent 
recurrences. Other focal CNS manifestations, such as demyelinating syndrome, transverse myelitis, 
chorea, migraine and seizures, when associated with aPL, may also benefit from anticoagulation. 
Severe diffuse CNS manifestations, such as acute confusional states, generalized seizures, anxiety, 
mood disorders and psychosis generally require corticosteroids in the first instance. High dose of 
corticosteroids may only be used in severe cases and, preferably for short periods. Pulse intravenous 
cyclophosphamide therapy may help when more severe manifestations are refractory to corticosteroids 
and other immunosuppressive agents, generally when response is not seen in three to five days. 
Plasmapheresis, intrathecal methotrexate and dexamethasone, iloprost, azathioprine and mycophenolate 
mofetil deserve further studies to confirm their usefulness in the treatment of NPSLE. It is imperative 
to enroll homogeneous groups of patients in the design of multicentre randomized controlled trials with 
good sample sizes and accurate power calculations to give an answer to the many questions currently 
remaining in the treatment of NPSLE, ultimately yielding to more effective treatments for this serious 
and potentially life-threatening manifestation of SLE. 
REVIEW OF LITERATURE   
The ACR nomenclature and case definitions for NP-SLE have been validated in a cross-sectional, 
population-based study by Ainiala et al [9]. Forty-six SLE patients were compared with 46 individuals 
randomly selected from the Finnish population register and matched by age, gender, education, and 
municipality of residence.  At least one NP manifestation was identified in 91% of the 46 Finnish 
patients compared with 54% of controls. This provided an odds ratio of 9.5 (95% confidence interval 
(CI) 2.21 to 40.8) for the occurrence of an NP event and specificity of 46%. In view of the high 
prevalence of NP disease in both SLE and controls, the authors suggested several modifications to how 
the criteria should be used. Thus, by excluding headache, anxiety, mild depression, mild cognitive 
impairment and polyneuropathy without electro physiologic confirmation, the prevalence of NP disease 
fell from 91% to 46% in SLE patients and from 54% to 7% in controls. This provided an odds ratio of 
7.0 (95% CI 2.09 to 23.47) and specificity of 93%. 
In addition to the study of Ainiala et al, at least four other groups [10–13] have used the ACR 
nomenclature to classify their SLE cohorts for NP-SLE the overall prevalence of NP disease in these 
patient populations has varied between 37% and 95%. The most common 4 of the 19 NP syndromes in 
each of these five SLE cohorts are cognitive dysfunction, headache, mood disorder and cerebrovascular 
disease. Most of the other NP syndromes were infrequent, with a prevalence of less than 1% in most 
cases. Of interest, the range in the prevalence of NP-SLE in these studies was as wide as that reported 
before the introduction of the ACR nomenclature. In previous studies, NP disease was reported in 14% 
to 75% of SLE patients [14–16]. 
Cognitive function
Cognitive dysfunction, assessed using neuropsychologic assessment techniques, has been reported in 
up to 80% of SLE patients [9], although most studies have found prevalence between 17% and 66% 
[14, 43]. These tests evaluate the functional integrity of the CNS through systematic assessment of 
performance on specific tasks. The range in prevalence of cognitive impairment in SLE [14, 43] is most 
likely because of differences in selection of patients for study and lack of uniform definitions for 
cognitive impairment. There is no specific or unique pattern of cognitive impairment in SLE, and many 
individual patients have subclinical deficits. 
For example, a review of 14 cross-sectional studies of cognitive function in SLE revealed subclinical 
cognitive impairment in 11% to 54% of patients (43). The outcome of cognitive impairment in SLE 
patients has been examined in several studies. For example, in a 5-year prospective study of 70 SLE 
patients using a standardized panel of neuropsychologic tests [44], the prevalence of overall cognitive 
impairment in SLE patients fell from 21% to 13% over the period of study. Five patterns of cognitive 
performance were observed over the 5-year period. Eighty-three percent of patients were either never 
impaired or had resolution of cognitive impairment without specific therapeutic interventions. An 
additional 13% of patients demonstrated an emerging or fluctuating pattern of impairment, and only 
4% (two patients) showed persisting deficits that were stable over time. 
Similar benign changes in cognitive performance over time have been reported by Waterloo et al [74] 
in 28 patients over 5 years, by Hay et al [75] in a 2-year prospective study, and by Carlomagno et al 
[76]. Predictors of cognitive decline over time also have been examined. In a study by Hanly et al [44], 
when patients who were cognitively impaired at the initial assessment were compared with those who 
were not impaired, the differences between groups in tests of recent memory and delayed free recall 
decreased over 5 years. A similar result was reported by Waterloo et al [74]. 
Patients who had clinically overt NP-SLE at any time in their disease course, however, had a 
statistically significant decline in memory performance over 5 years when compared with patients who 
did not have a history of clinically overt NP-SLE [44]. The association between cognitive function and 
anticardiolipin (aCL) antibodies has been examined in several cross-sectional and prospective studies. 
In a study, 51 SLE patients were divided into those who were persistently aCL antibody positive or 
negative on the basis of up to seven antibody determinations over a 5-year period [34]. The relative 
change in performance on individual neuropsychologic tests then was compared between patients who 
were antibody positive and negative. Those who were persistently IgG aCL antibody positive 
demonstrated a greater reduction in psychomotor speed compared with those who were antibody 
negative. In contrast, patients who were persistently IgA aCL antibody positive had significantly poorer 
performance in conceptual reasoning and executive ability. These data suggest that IgG and IgA aCL 
may be responsible for long-term subtle deterioration in cognitive function in SLE patients.
Headache
The association between SLE and headache is controversial. The reported prevalence of headache has 
varied widely between 24% and 72% [9–13], but the prevalence of headache in the general population 
is also high, with up to 40% of individuals reporting a severe headache at least once per year. Two of 
the most recent studies [77, 78], which were methodologically more robust than earlier work showed 
no increase in the prevalence of headache in SLE. Although headache may be a component of active 
SLE in individual patients, particularly in patients who have active systemic disease, it is more likely 
that most headaches in SLE patients are unrelated to SLE [79].
Psychosis, mood disorders, and anxiety
Psychosis is reported in up to 8% of SLE patients [9–13], and it is characterized by either the presence 
of delusions (false belief despite evidence to the contrary) or hallucinations (perceptual experiences 
occurring in the absence of external stimuli). The latter are most frequently auditory. Psychosis is a rare 
but dramatic manifestation of NP-SLE, and when present it must be distinguished from other causes, 
including drug abuse, schizophrenia, and depression. Depression and anxiety are common symptoms in 
lupus patients and occur in 24% to 57% of patients [9–13, 31]. As there are no features of these 
syndromes that are unique to SLE patients, however, there is often uncertainty about the etiology and 
attribution in individual cases. The association between psychosis, depression, and anti-P antibodies in 
SLE is supported by some but not all studies [29-31].
Cerebrovascular disease
The many forms of cerebrovascular disease are reported in 5% to 18% of SLE patients [9–13] and are 
likely multifactorial in etiology. Accelerated atherosclerosis is recognized in SLE, particularly in 
relation to coronary heart disease, where there is a 5 to 10 times higher rate of events compared with 
control populations. This also contributes to the increased rate of cerebrovascular events in SLE. An 
additional etiologic factor is the prothrombotic state as a consequence of antiphospholipid antibodies, 
which provides a rationale for therapeutic intervention with anticoagulants in selected cases.
Seizures
Generalized and focal seizures are reported in 6% to 51% [9–13] of patients and may occur either in the 
setting of active generalized multisystem lupus or as isolated neurologic events. Their occurrence 
frequently is associated with the presence of antiphospholipid antibodies [12], which are associated 
with microangiopathy, arterial thrombosis, and subsequent cerebral infarction.
Uncommon presentations
The  rare manifestations of nervous system disease in SLE that occur no more frequently than in 1% to 
3% of patients are movement disorder, demyelinating syndromes, myelopathy, myasthenia gravis, 
Guillain-barre syndrome, autonomic disorder, Plexopathy and aseptic meningitis[9–13, 16]. Clinical 
and neuroimaging evidence of demyelination has been described and may be indistinguishable from 
multiple sclerosis. This may represent a concordance or overlap of two autoimmune conditions. 
Transverse myelopathy [80] and chorea [81] present acutely and frequently are associated with 
antiphospholipid antibodies. Although an arterial thrombotic event is a likely mechanism for transverse 
myelopathy, the cause of chorea is less clear, and there has been speculation that it may be a 
consequence of a direct interaction of antiphospholipid antibodies with neuronal structures in the basal 
ganglia.
Neuropathy
A sensorimotor neuropathy has been reported in up to 28% [9–13] of SLE patients and frequently 
occurs independently of other disease characteristics [82]. The abnormalities are persistent, but in one 
study, 67% of patients had no change in their neuropathy over a 7-year period [90]. A controlled 
immunohistologic study of skin biopsies in SLE patients has demonstrated involvement of small nerve 
fibers [83].
Clinical impact and prognosis of neuropsychiatric systemic lupus erythematosus
The clinical impact of NP events in SLE has been determined by examining the association with 
several clinical indicators including quality of life. In a recent study [11], NP events were associated 
with significantly lower scores on most subscales of the SF-36, a generic self-report measure of quality 
of life, and with higher fatigue scores. These associations were present regardless of the attribution of 
the NP event to SLE or an alternative etiology, but they did not occur in patients who have a history of 
renal disease. 
The data indicate that NP events in SLE patients, regardless of their etiology and attribution, have a 
negative impact on quality of life. In a study [45] 70% of patients who have cognitive difficulties were 
able to maintain their work capacity, and 86% had no change in their social functioning. Relatively few 
studies have examined the course of NP-SLE over time. Karassa et al [46] examined the prognosis of 
NP disease in 32 patients who had been hospitalized for NP-SLE and followed for 2 years. The 
outcome was generally favorable, with either substantial improvement (69%) or stabilization (19%) 
accounting for most cases. A high number of prior NP events and the occurrence of the 
antiphospholipid syndrome were predictors of an unfavorable clinical outcome at 2 years. 
There is no consensus in the literature on the asso ciation between NP-SLE and mortality. Some studies 
report increased mortality [47, 48] in SLE patients who have NP disease, and others report no such 
association [42, 49]. One cause of mortality in SLE is suicide, which has been reported in association 
with NP manifestations in a recent study involving a small number of patients [50].
NPpSLE
The prevalence of neuropsychiatric disease within different pSLE cohorts has been reported to vary 
from a low of 20% to a high of 95% of patients. [84, 85, 87]       
HEADACHE
In children with NP-pSLE headache is the most common symptom occurring in 50–75% of patients. 
[84, 87] In contrast, only 6–22% would meet the criteria for ‘lupus headache’. In Toronto NP-pSLE 
cohort 75% of children had headache, however in the majority of patients the headache was associated 
with other CNS disease and 25% had a headache as the sole CNS manifestation. In all patients with 
severe headache, cerebral vein thrombosis, CNS infection, inﬂammation of the cerebral arteries and 
other intracranial pathologies associated with SLE should be ruled out prior to accepting the diagnosis 
of isolated lupus headache.
Psychiatric manifestations
Following headache, psychiatric manifestations of pSLE are the most common manifestation. About 
12–40% of NP-pSLE children develop psychosis [86].The hallmarks of pSLE-associated psychosis are 
visual hallucinations. The presence of this type of hallucination helps to differentiate the organic 
psychosis associated with SLE from idiopathic schizophrenia of childhood. Visual hallucinations may 
be accompanied by auditory hallucinations and frequently the hallucinations are of  threatening nature. 
The most common mood disorder seen in pSLE is depression.[85] Depression may be an organic 
depression secondary to NP-SLE or a more reactive depression secondary to chronic disease, and rarely 
to corticosteroid use. Mania and bipolar disorder are uncommon.
Cognitive dysfunction is found in about 30% of NP-pSLE patients. The diagnosis is conﬁrmed when 
the child has a documented impairment in at least one of the cognitive domains of simple or complex 
attention, memory, visual-spatial processing, language, reasoning/problem solving, psychomotor speed 
and executive functions. Although there have been many studies in adults using standardized 
neuropsychiatric tests at diagnosis and in follow-up, few studies have been performed in pSLE. 
Cerebrovascular disease
The category of cerebrovascular disease (CVD) includes a spectrum of SLE- associated cerebral blood 
vessel abnormalities, ranging from involvement of inﬂammation of small arteries to cerebral vein 
thrombosis, which is seen in about 25% of NP-pSLE patients. More frequently pSLE patients present 
with multifocal enhancing MRI lesions suggestive of small vessel inﬂammation, with a normal 
angiogram. These patients may have diverse clinical presentation and ﬁndings include cognitive defects 
and headaches. Cerebral vein thrombosis, found in 15–25% of pSLE patients, is almost universally 
associated with antiphospholipid antibodies (aPL) and in particular with lupus anticoagulant (LAC). 
[89] Most patients with CVD present with a severe headache, and they may have associated seizures.
Seizures
Seizures are found in approximately 20% of NP-pSLE patients. In Toronto cohort experience, seizures 
are frequently associated with CVD and/or cognitive dysfunction.[91]  One study has suggested an 
association of aPL and seizures, but further studies are required to conﬁrm this observation.[90]Long-
term anticonvulsive therapy is frequently required as EEG abnormalities often persist.
Chorea
Chorea is present in approximately 5% of patients, although one study suggested that up to 20% of 
patients may have chorea. Chorea is almost universally associated with the presence of aPL, and with 
the decline of rheumatic fever in Western countries chorea is more likely to be secondary to the 
presence of aPL rather than to rheumatic fever. As PAPS (primary antiphospholipid syndrome) is 
infrequently seen in children and adolescents, chorea is most likely secondary to SLE even in the 
absence of other overt symptoms. Interestingly, despite a higher prevalence of APS in adults, chorea is 
more commonly seen in pSLE than in adult patients. [85-87] Most patients only have one episode of 
chorea, and unilateral chorea is seen more commonly than bilateral. [87]
Uncommon presentations
Less common CNS symptoms include diabetes insipidus, Parkinson’s syndrome, cranial nerve 
involvement and leuko encephalopathy.[84] Ocular involvement has been reported to occur in up to 
25% of cases, with pseudotumour cerebri,papilledema and visual disturbances being the most common 
ﬁndings.[84,87] Retinal vascular disease, consisting of arterial or venous occlusion, cotton wool spots, 
optic disc edema, retinal hemorrhages or ischemic optic neuropathy can be found in up to 10% of 
patients. The majority of these patients have detectable aPL.
Peripheral nervous system
Peripheral nervous system (PNS) involvement occurs in 5–15% of all patients with pSLE. [85, 86] It 
may occur with or without concomitant CNS involvement. Peripheral nerve involvement frequently 
involves both sensory and motor neurons and may be either a polyneuropathy or mononeuritis. 
Transverse myelitis was the most common PNS disease. Overall transverse myelitis, peripheral 
neuropathy and aseptic meningitis each occur in approximately 1–5% of patients.[86].Less commonly, 
PNS involvement includes polyneuropathy, mononeuritis, myasthenia gravis, cranial neuropathy, 
demyelinating disease, and Guillain Barre syndrome.[84] Unlike in adults with SLE, autonomic 
dysfunction has been only rarely reported in pediatric patients.
INDIAN STUDIES
In a study of 334 SLE patients by Chandrasekran AN and Porkodi R et al, the NPSLE manifestations 
were seen in 32.4% of patients. The most common features were headache in 46(43.6%), seizures in 
33(31.1%),psychosis in 23(21.7%) and depression in 24(22.6%).[94]Another study by Bichile LS et al 
showed the incidence of NPSLE was in 26(20.96%) out of 124 patients. The common manifestations 
are seizures in 14(53.84%), psychosis in (42.3%) and CVA in 3(11%).[95]In a review of 329 cases of 
SLE from Northern  india by Malaviya AN et al showed that the occurrence of NPSLE was 63% and 
the incidence of NPSLE was 23.2% in a study by Amen SN et al from Western india.[96,97]
AIM OF THE STUDY
1) To  study  the  various  neurological  manifestations  in  patients  with  systemic 
lupus erythematosus.
2) To study the various psychiatric manifestations in patients with systemic lupus 
erythematosus.
3) To compare the neuropsychiatric manifestations between childhood and adult 
SLE patients
MATERIALS AND METHODS
One hundred consecutive patients (7 males, 93 females) with systemic lupus erythematosus who 
attended the Department of Rheumatology, Madras Medical College, Chennai were included as the 
study population. This is a prospective study done during November 2005-March2008.
 INCLUSION CRITERIA             
Patients who fulfilled 1997 Revised ACR Classification Criteria for systemic lupus erythematosus were 
included. 
EXCLUSION CRITERIA                            
1) Patients with overlap syndrome were excluded.
2) Patients with history of head injury.
3) Patients with chronic renal failure.
4) Patients with alcoholism.
All the selected patients were subjected to clinical examination including detailed neurological 
evaluation. The psychiatric evaluation was done with the help from Institute of Mental health, Madras 
Medical College.  
Psychiatric Assessment
1) Mini Mental State Examination (MMSE), which evaluates cognitive abnormalities and 
was considered pathologic when the score was lower than 24/30.
2) General Health Questionnaire, a 20 item questionnaire to detect the psychopathology by 
means of four independent subscales: somatic symptoms of psychological nature, 
anxiety, depression and social disability.
3) Hospital Anxiety Scale (HAS), which evaluates symptoms of anxiety.
4) Hospital Scale for Depression (HDS), which evaluates symptoms of depression.
Assessment of SLE Activity
The disease activity was measured using the SLE Disease Activity Index (SLEDAI).It consists of 24 
variables, grouped according to nine organ systems (including some immunological tests), and the 
range possible SLEDAI scores is 0-105 
Patients with neuropsychiatric manifestation were classified according to 1999 Case definitions for 19 
NPSLE syndromes.
LIMITATIONS OF THIS STUDY
    1) Imaging studies for brain function like SPECT, PET or MRS are not done.
    2) Tests for Antineuronal and Antiribosomal antibodies are not done.
LABORATORY TESTS
Hematological evaluation including complete hemogram and peripheral smear study and biochemical 
parameters including blood glucose, urea, serum creatinine, liver function tests and fasting lipid profile 
were done for all patients. CRP was done by latex agglutination method.
ANA
ANA was done by indirect immunofluorescence using mouse liver substrate and Hep2 cells if negative 
by mouse liver substrate.
Anti-dsDNA
 The detection of Immunoglobin IgG antibodies to dsDNA was done by CALBIOTECH INC dsDNA 
Ig ELISA test system. The method being as follows; Diluted patient serum is added to wells coated 
with purified dsDNA antigen. All unbound materials are washed away and the conjugate is added to 
bind to the antigen-antibody, if present. Excess conjugate is washed off and substrate is added. The 
plate is allowed to the hydrolysis of substrate by the enzyme. After addition of stop solution, OD 
reading is measured by BIORAD ELISA reader. The intensity of the color generated is proportional to 
the amount of specific antibody in the sample and is given in OD values. The antibody index is 
calculated from the OD values according to instructions in the kit. The test is positive if the antibody 
index is >1.1 and negative if it is <0.9.    
COMPLEMENT
The complement levels were measured using by Single Radial Immune Diffusion plates. The procedure 
consists of immunoprecipitation in agarose gel between an antigen and its homologous antibody. It is 
performed by incorporating the anti C3 and anti C4 antibodies uniformly throughout a layer of agarose 
gel and antigen is added into the wells duly punched in the gel.  Antigen diffuses radially out of the 
well into the surrounding gel and a visible ring of sharp precipitation forms where the antigen and 
antibody reacted in the zone of equivalence. A quantitative relationship does exist between ring 
diameters and complement concentration. The reference value for C3 is 80-160mg/dl and for C4 is 
20-40mg/dl.  
Cryoglobulin was tested by preparing the centrifuged serum and keeping it at 4 degree C and   reading 
it after 72 hours for the gel precipitate at the bottom of conical tube.
Lupus Anticoagulant Study including activated partial prothrombin time, dilute Russel viper venom 
test and Kaolin clotting time were done. Coombs test including both direct and indirect was done. 
aCL IgG and IgM by ELISA
It was done using commercial ELISA kit (CAL BIOTECH, INC). Diluted patient serum is added to 
wells coated with purified aCL antigen.aCL specific Ig G or IgM antibody, if present, binds to the 
antigen. All unbound materials are washed away and the enzyme conjugate is added to bind to the 
antibody-antigen complex, if present. Excess enzyme conjugate is washed off and substrate is added. 
The plate is incubated to allow the hydrolysis of the substrate by the enzyme. The intensity of the color 
generated is proportional to the amount of specific antibody in the sample. The OD values are recorded 
and the antibody index is calculated as per the instructions in the kit.   The optical densities were read 
by an ELISA reader (Tecan, Austria) at 450 nm. GPL and MPL units of a serum sample were read 
against the standard curve. A value of 10 -15 GPLwas taken as low positive, 15 -80 GPL as medium 
and above 80 GPL as high positive. 
Electroencephalogram [EEG] and cerebrospinal fluid examination were done if necessary and patient’s 
consent was available. Radiological evaluation like X-ray chest, Ultrasound Abdomen and 
Echocardiogram were done for all patients. HRCT chest was done if necessary.12 lead standard resting 
electrocardiogram was recorded in all 100 patients
                      RESULTS
The clinical, laboratory and imaging profile of 100 patients who satisfied the 1997 revised ACR 
classification criteria for SLE were analyzed. The 100 patients were divided into as to whether they 
belong to childhood SLE or adult SLE.
TABLE 1: AGE-WISE DISTRIBUTION
No of patients Mean age +SD t-test
SLE 69 26.75+8.65
pSLE 31 12.84+3.38
5.81
P<0.001
NPSLE 41 28.05+10.39
NPpSLE 15 13.33+3.48
3.20
P<0.01
       The age range was 3 years to 55 years. The maximum number of cases occurred in 20 to 35 years. 
The mean age of study group is 22.44 years and the mean age in patients with NPSLE is 24.10 years. 
The female to male ratio was 14:1.The mean duration of illness in patients with NPSLE is 3.74 years. 
Table-2: SEX-WISE DISTRIBUTION
Group
Male Female
No. % No. %
SLE 4 5.78 65 94.22
pSLE 3 9.68 28 90.32
NPSLE 1 2.44 40 97.56
NPpSLE 1 6.67 14 93.33
TABLE-3: CLINICAL PROFILE OF STUDY PATIENTS
PARAMETERS N=100
Age (mean) in yrs 22.44
Female: Male 14:1
Duration of the disease (mean) in yrs 2.10
Mean SLEDAI 12.57
Constitutional features 82
Mucocutaneous features 96
Musculoskeletal features 74
Pulmonary involvement 10
Cardiac involvement 16
Renal involvement 30
NPSLE 56
Out of 56 patients with NP-SLE manifestations, 41 patients belong to adult group and 15 patients are 
children (Table3, 4, 5). The most common manifestations in adults are seizures (39%), headache and 
CVA (26.8%). In childhood group, the most common manifestations are seizures (80%), 
headache(26.6%)and psychosis(26.6%).The analysis of the other manifestations showed that the renal 
involvement was seen in 23(41%) NP-SLE patients.     
TABLE-4: PROFILE OF PEADIATRIC SLE CASES WITH 
NEUROPSYCHIATRIC FEATURES
PARAMETERS CNSN=14
PNS
N=1
PSY. INVOLEMENT
N=8
Duration of the disease 
(mean) in yrs 
3.02 4 1.7
Constitutional features 14 1 4
Mucocutaneous features 10 1 6
Pulmonary involvement - - -
Cardiac involvement 6 - 3
Renal involvement 10 1 4
TABLE-5: PROFILE OF ADULT SLE WITH 
NEUROPSYCHIATRIC FEATURES
PARAMETERS CNSN=40
PNS
N=1
PSY.INVOLMENT
N=35
Duration of the disease 
(mean) in yrs 
4.09 0.2 2.67
Constitutional features 24 - 22
Mucocutaneous features 32 1 32
Pulmonary involvement 2 - 2
Cardiac involvement 6 - 4
Renal involvement 12 - 8
TABLE-6: NEUROPSYCHIATRIC MANIFESTATIONS IN SLE 
PATIENTS
NP-SLE Total no. ptsN=56
pSLE
N=15
SLE
N=41
CNS 54(96.4%) 14(93.3%) 40(97.5%)
PNS 2(3.5%) 1 1
Aseptic meningitis - - -
CVA 14(25%) 3 (20%) 11(26.8%)
Demyelinating syndrome - - -
Headache 15(26.7%) 4(26.6%) 11(26.8%)
Movement disorder - - -
Myelopathy 2(3.5%) 2(4.8%)
Seizure disorders 28(50%) 12(80%) 16(39%)
GBS - - -
Autonomic disorder - - -
Mononeuropathy - - -
Myasthenia gravis - - -
Cranial neuropathy 2(3.5%) 1 1
Plexopathy - - -
A/c confusion state - - -
Anxiety disorder 11(19.6%) 2(13.3%) 9(21.9%)
Cognitive dysfunction 12(21.4%) 2(13.3%) 10(24.3%)
Mood disorder 12(21.4%) 1 11(26.6%)
Psychosis 10(17.8%) 4(26.6%) 6(14.6%)
TABLE 7 OCULAR INVOLVEMENT
TYPE OF LESION NP-SLE NPpSLE ADULT NPSLE
N=56 n=15 n=41
Abnormal findings 10(17.8%) 6(40%) 4(9.7%)
Optic neuritis 2 2 -
Cotton wool exudates 3 2 1
Retinal vasculitis 3 1 2
Papilledema 1 - 1
Cortical blindness 1 1 -
TABLE 8 RENAL INVOLVEMENT
LUPUS NEPHRITIS SLE n=100 NPSLE n=56
Abnormal biopsy findings 30(30%) 23(41%)
Class 2 3 2
Class 3 6 4
Class 4 16 14
Class 5 5 3
Class 6 - -
TABLE-9: LABORATORY PROFILE OF STUDY PATIENTS
Tests Total ptsN=100
pSLE
N=31
SLE
N=69
Low Haemoglobin(<10G) 53 19 34
Low platelets(<1lakh) 16 6 10
High ESR 23 10 13
CRP 15 9 6
dsDNA 51 18 23
Sm Ab 35 15 20
APA positivity(aCL IgG,M,LAC) 34 10 24
Low c3,c4 19 6 13
Positive Coombs test 6 2 4
Cryoglobulins 9 1 8
Abnormal Lipid profile 32 8 24
TABLE-10: LABORATORY PROFILE OF NP-SLE PATIENTS
Tests Total ptsN=56
pSLE
N=15
Adult SLE
N=41
Low Hb(<10g) 37(66%) 12(80%) 25(60.9%)
Low platelets(<1lakh) 8(21.6%) 3(20%) 5(12.1%)
High ESR 19(33.3%) 7(46.6%) 12(29.2%)
CRP 9(16%) 5(33.3%0 4(9.7%)
dsDNA 29(51.7%) 9(60%) 20(48.7%)
Sm Ab 20(35.7%) 6(40%) 14(34.1%)
APA positivity(aCL IgG,M,LAC)  26(46%) 8(53.3%) 18(43.9%)
Low c3,C4 14(28%) 4(26.6%) 10(24.3%)
Positive Coombs test 5(8.9%) 2(13%) 3(7.3%0
Cryoglobulin 7(12.5%) 1 6(14.6%)
High LDL 12(21.4%) 2(13%) 10(24.3%)
Laboratory analysis of NP-SLE patients showed anemia in 37patients (66%), thrombocytopenia in 
8(21.6%), elevated CRP in 9(16%) and dsDNA was positive in 29(51.7%).LAC was positive in 9 
patients (16%), aCL IgG in 24(42.8%) and aCL IgM was positive in 9(16%).Low complement levels 
were detected in 14(25%).  
TABLE-11: NP-SYNDROMES IN APA POSITIVE PATIENTS
TYPE OF LESION
APA POSITIVE PATIENTS
NPpSLE n=8 NPSLE n=18
CVA 2 10
Seizures 3 6
Cranial Neuropathy 1 1
Psychosis - 3
TABLE 12 EEG FINDINGS
Abnormality NPSLE with seizures n=28
NPSLE without seizures
n=28
Diffuse slow waves 8(28.5%) 4(14.2%)
Focal epileptic activity 4(14.2%) -
Normal 16(57.1%) 24(85%)
Out of 56 patients with NPSLE manifestations, Cerebro spinal fluid examination was done in 15 
patients.  The analysis reveals pleocytosis in three patients and high protein concentration in four 
patients.   
TABLE-13: MRI FINDINGS
TYPE OF LESION NP-SLE N=56 NPpSLE n=15 NPSLE N=41
Abnormal findings 25 (44.6%) 3(20%) 22(53.6%)
Ischemic lesion 14 (25%) 3(20%) 11(26.8%)
Small high-density 
lesion
4 (7%) - 4(9.7%)
Cortical atrophy 5(8.9%) - 5(12.1%)
High intense lesion in 
spinal cord 
2(3.5%) 2(4.8%)
DISCUSSION
Neuropsychiatric manifestation in SLE is one of the major organ involvement which was reported 
frequently in the literature. This study was undertaken to assess the neuropsychiatric complications in 
both paediatric and adult onset SLE.The incidence of NP-SLE in our study population of 100 patients 
is 56%.The incidence reported in previous studies varies from 37% and 97% [9, 10-13]. 93% of our 
patients were females as the disease occurs predominantly in females. Of the 56 patients with NPSLE 
only two were males. 
The age of the study population ranges from 2.5 years to 55 years.31% of patients belongs to paediatric 
onset SLE. 84% of the study group was below the age of 30 years and only 3 were above 50 years so 
that the neurological problems due to aging are minimized. The mean age of patients with 
neuropsychiatric manifestation was 24.10 years (range 12 to 53 years) and mean latency of NPSLE 
from initial systemic involvement was 3.74 years (range 0-6years).
In a study by Ainiala et al 2001[9], the four common neuropsychiatric SLE syndromes as defined by 
ACR Nomenclature committee were cognitive dysfunction (80%), headache (54%), polyneuropathy 
(28%) and cerebrovascular disease (15%). In a study by Brey et al 2002 [10], the four common 
syndromes were cognitive dysfunction (69%), headache (57%), mood disorder (40%) and anxiety 
(24%). In Sanna et al study, the common syndromes were headache (24%), cerebrovascular disease 
(18%), seizures (8%) and psychosis (8%). In Hanley et al study, the common syndromes were 
headache (28%), mood disorder (14%), cerebrovascular disease (5%) and seizures (6%). In our study 
population of 69 adult patients, the four common syndromes were seizures, headache, cerebrovascular 
disease and mood disorder.  The common syndromes among 31 paediatric patients were seizures, 
headache, cerebrovascular disease and psychosis. 
Neurological manifestations as initial presenting feature of SLE occurred in 7 patients. The ACR 
criteria for SLE require at least four characteristic features occur at anytime during the course, not 
necessarily simultaneously. Although the criteria were not fulfilled at early stage, the later emergence 
of more typical features of the disease confirmed the diagnosis in each case. Out of seven patients, four 
had seizures, two had cerebrovascular disease and one had paraplegia. 
Out of 14 patients with cerebrovascular disease, 11 belong to adult group and three belongs to 
paediatric onset group. The majority presented with persistent hemiparesis and facial nerve weakness. 
There were no other relevant risk factors like hypertension, diabetes mellitus, hypercholesterolemia or 
smoking in any of these patients.  The cerebrovascular disease was reported in 5% to 18% of SLE 
patients [9-13]. Isolated LMN type of cranial nerve involvement was seen in two patients. 
Seizures are already known to occur in 6% to 51 % of lupus patients [9-13] compared with 0.5% to 1% 
in the general population. They are usually primary generalized, but partial episodes also occur. In our 
study the most common NP-SLE syndrome is seizure in both NPpSLE group (80%) and in adult 
NPSLE patients (39%). Seizure was the first SLE symptom in four patients. 
The analysis of psychiatric involvement showed that the prevalence of cognitive dysfunction ranged 
between 17% and 66%. [14, 44-45], psychosis (8%) and depression and anxiety(24%-57%)[9-13] .In 
our 56 NPSLE patients , cognitive dysfunction and mood disorders occurred in twelve patients, anxiety 
in eleven and psychosis in ten patients. In four patients, psychosis was present as isolated feature of 
NP-SLE.
In our study, ocular involvement was seen in ten patients. The various manifestations were optic 
neuritis in two, bilateral cortical blindness in one, papilledema in one, cotton wool exudates in three, 
bilateral retinal vasculitis in three patients. Four patients showed APA positivity. Ocular involvement 
had been reported to occur in up to 25% of cases. [84, 87] The most commonly observed systemic 
features in our study population were constitutional (82%), skin and mucosal involvement (96%), joints 
(74%) and renal involvement (30%). Skin, joint and renal involvements were most frequently observed 
features that preceded CNS complications.  
The classical finding of a low CRP but elevated ESR was seen in 15 patients. In our study APA 
positivity was present in 26(46%) patients with neuropsychiatric manifestations. In a review of 1000 
SLE patients, Love and Santoro reported neuropsychiatric manifestations in 38% of patients who had 
antiphospholipid antibodies compared with 21% of patients who did not have this antibodies 
[33-3].The prevalence of APA positivity in patients with various neuropsychiatric syndromes were 
57%(8) in cerebrovascular disease, 25%(7) in seizure and 40%(4) in psychosis. These results were 
similar to the earlier reports regarding the association of APA positivity and NPSLE [92-93]. 
Electro encephalogram (EEG) was abnormal in 16 out of 56 patients with NPSLE. EEG was normal in 
16 patients with seizures. The most common abnormality of diffuse slow wave was seen in 12 patients. 
Many studies suggest that EEG was rarely helpful in diffuse CNS disease and were usually abnormal 
only when seizures were present.
MRI and CT brain scans were done in 56 patients. Abnormalities on T2-weighted MRI images were 
found in 19% [51] to 70% [52] of SLE patients. The application of fluid attenuating inversion recovery 
(FLAIR) to dampen the CSF signal highlights the areas of edema enhancing the utility ofT2 weighted 
images. In our study thirty two percent of CT brain and 44.6% of MRI brain scans were abnormal. The 
analysis of CT results showed that it is very useful for identifying large infarcts and haemorhages. 
Perisulcal cortical atrophy was seen in four patients.
MRI features were often non specific. Abnormal scans were associated focal neurological deficits, 
normal scans with more diffuse phenomena such as headache and seizure. Diffuse presentations were 
associated with subcortical, small, multifocal and bilateral white matter hyper intensity lesions and 
patchy hyper intensities in the gray matter that usually not confined to the territories of major cerebral 
arteries.  
CONCLUSION
There was a female predominance in the patients with neuropsychiatric manifestations due to systemic 
lupus erythematosus.
The Neuropsychiatric manifestations were present in 56% of our study population. The CNS 
involvement was seen in 96.4% of patients with neuropsychiatric manifestations.
The four common NP-SLE syndromes in adult patients were seizures, headache, mood disorder and 
cerebrovascular disease and in paediatric patients seizures, headache, cerebrovascular disease and 
psychosis. Out of 30 patients with renal involvement, 23 patients had neuropsychiatric manifestations. 
The APA positivity was seen in 46% of patients with NP-SLE syndromes. It was associated with 
cerebrovascular disease in twelve out of fourteen patients.
Out of 28 patients with seizures, nine had APA positivity and six had abnormal MRI findings.   The 
most common MRI finding was focal ischemic lesion in both adult and paediatric patients.  
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APPENDIX-1      ABBREVIATION CODE
NPSLE Neuropsychiatric Systemic Lupus Erythematosus
NPpSLE Paediatric Neuropsychiatric Systemic lupus 
erythematosus
ACR American college of Rheumatology
CRP C-reactive protein
dsDNA Double stranded DNA
Sm Ab Anti –smith antibody
aCL IgM, G Anticardiolipin antibody
LAC Lupus anticoagulant
aPL Antiphospholipid antibody
C3,C4 Compliment 
MRI Magnetic resonance imaging
DWI diffusion weighted imaging
FMRI functional MRI
MRA magnetic resonance angiography
MRS magnetic resonance spectroscopy
MTI magnetization transverse imaging
PET positron emission tomography
SPECT Single photon emission computed tomography. 
APPENDIX- 2       PATIENT CONSENT FORM
Study title        :   A STUDY ON NEUROPSYCHIATRIC LUPUS 
PATIENTS
APPENDIX-3
CASE RECORD FORM
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VITAL SIGNS        PULSE                               BP                    TEMP             RR
CONSTITUTIONAL FEATURES
MUCOCUTANEOUS FEATURES
RENAL/GIT
CARDIOPULMONARY/PERIPHERALVASCULATURE
CNS
HIGHERFUNCTION                                            CRANIALNERVES
SPINOMOTOR SYSTEM                                     SENSORYSYS
CEREBELLAR FUNC                                          GAIT/SPINE
PSYCHIATRIC ASSESSMENT
MINIMENTALSCORE                  (<24/30)
ANXIETY/MOOD DISORDER / PSYCHOSIS / COGNITIVE DYSFUNCTION ACUTE 
CONFUSIONAL STATE.
INVESTIGATION
BASIC
HB                      TC              DC       ESR          CRP             PLO.    NA   K   HCO3
CREAT                                   SUGAR                                             UREA 
LIPID   PROFILE
IMMUNOLOGICAL
ANA           dsDNA      ENA          aCL            LAC       C3, C4 LEVELS   COOMBS TEST
SPECIAL INVESTIGATION
EMG/NCS                         EEG                        CSF
HPE
IMAGING
CT BRAIN                     MRI/MRA/MRV
ASSESSMENT
SLEDAI
SLICC
 
APPENDIX – 4
The Mini-Mental Status Examination
Orientation Points
Name: season/date/day/month/year 5 (1 for each name) 
Name: hospital/ﬂoor/town/state/country 5 (1 for each name) 
Registration 
Identify three objects by name and ask 
patient to repeat 
3 (1 for each object) 
Attention and calculation 
Serial 7s; subtract from 100 (e.g., 93– 
86–79–72–65) 
5 (1 for each subtraction) 
Recall 
Recall the three objects presented earlier 3 (1 for each object) 
Language 
Name pencil and watch 2 (1 for each object) 
Repeat “No ifs, ands, or buts” 1 
Follow a 3-step command (e.g., “Take 
this paper, fold it in half, and place it 
on the table”) 
3 (1 for each command) 
Write “close your eyes” and ask patient 
to obey written command 
1 
Ask patient to write a sentence 1 
Ask patient to copy a design       (e.g., in-
tersecting pentagons) 
1 
TOTAL 30 
APPENDIX –5 THE GENERAL HEALTH QUESTIONNAIRE
(20 ITEM VERSION)
1. Been able to concentrate on whatever you are doing?
a) Better than usual b) Same as usual
c) Less than usual d) Much less than usual
2. Lost much sleep over worry?
a) Not at all b) No more than usual
c) Rather more than usual d) Much more than usual
3. Felt that you are playing a useful part in things?
a) More than usual b) Same as usual
c) Less than usual d) Much less useful
4. Felt capable of making decision about things?
a) More than usual b) Same as usual
c) Less useful than usual d) Much less useful
5.  Felt constantly under strain?
a) Not at all b) No more than usual
c) Rather more than usual d) Much more than usual
6. Felt that you could overcome your difficulties?
a) Not at all b) No more than usual
c) Rather more than usual d) Much more than usual
7. Been able to enjoy your normal day to day activities?
a) More than usual b) Same as usual
c) Less useful than usual d) Much less useful
8. Been able to face up to your problems?
a) More than usual b) Same as usual
c) Less useful than usual d) Much less useful
9. Been feeling unhappy and depressed?
a) Not at all b) No more than usual
c) Rather more than usual d) Much more than usual
10. Been losing confidence in yourself?
a) Not at all b) No more than usual
c) Rather more than usual d) Much more than usual
11. Been thinking of yourself as a worthless person?
a) Not at all b) No more than usual
c) Rather more than usual d) Much more than usual
12. Been feeling reasonably happy, all things considered?
a) More than usual b) Same as usual
c) Less useful than usual d) Much less useful
13. Been managing to keep yourself busy and occupied?
a) More than usual b) Same as usual
c) Less useful than usual d) Much less useful
14. Been getting out of the home as much as usual?
a) More than usual b) Same as usual
c) Less useful than usual d) Much less useful
15. Felt on the whole you were doing things well?
a) Better than usual b) About the same
c) Less well than usual d) Much less well
16. Been satisfied with the way you are carried out your task?
a) More satisfied b) About the same as usual
c) Much less satisfied d) Less satisfied than usual
17. Been taking things hard?
a) Not at all b) No more than usual
c) Rather more than usual d) Much more than usual
18. Found everything getting on top of you?
a) Not at all b) No more than usual
c) Rather more than usual d) Much more than usual
19. Been feeling nervous and strung up all the time?
a) Not at all b) No more than usual
c) Rather more than usual d) Much more than usual
20. Found at times you could not do anything because your nerves were too bad?
a) Not at all b) No more than usual
c) Rather more than usual d) Much more than usual
APPENDIX –6 DEPRESSION SCALE
PLEASE “√  “THE APPROPRIATE COLUMN FOR EACH QUESTION 
(GIVE ONLY 1 ANSWER PER ROW)
I still enjoy the 
things I used to 
enjoy
Definitely 
as much 
Not quite as 
much
Only a little Hardly at all
0 1 2 3
I can laugh and 
see the funny 
side of things
As much as 
I always 
could
Not quite so 
much now
Definitely 
not so much 
now
Not at all
0 1 2 3
I feel cheerful Not at all Not often Sometimes A lot
3 2 1 0
I feel as it I have 
slowed down
Nearly all 
the time
very often Sometimes Not at all
3 2 1 0
I have lost 
interest in my 
appearance
Definitely I don’t take so 
much care as I 
should
I may not 
take as much 
care
I take just as 
much care 
as ever
3 2 1 0
I look forward 
with enjoyment 
to things
As much as 
ever
Rather less 
than I used to
Definitely 
less than 
before
Hardly at all
0 1 2 3
I can enjoy a 
good book or 
radio or TV 
programme
often Sometimes Not often Very 
selection
0 1 2 3
Depression Sub score
APPENDIX – 7 ANXIETY SCALE
PLEASE “ √“THE APPROPRIATE COLUMN FOR EACH QUESTION 
(GIVE ONLY 1 ANSWER PER ROW)
I feel tense Most of 
time 
A lot of time Occasionally Not at all
3 2 1 0
I get frightened 
feelings, that 
something bad is going 
to happen
Quite badly Not too 
badly
A little Not at all
3 2 1 0
I worry a lot A great deal 
of time
A lot of time From time to 
time
Only 
occasionally
3 2 1 0
I can sit at ease and 
feel relaxed
Definitely Usually Not often Not at all
0 1 2 3
I get frightened 
feelings, like 
butterflies in stomach
Not at all Occasionally Quite often Not at all
0 1 2 3
I feel restless Very much Quite a lot Not very 
much
Not at all
3 2 1 0
I get sudden feelings of 
panic
Very often Quite often Not often Not at all
3 2 1 0
Anxiety Sub score: Name of the Doctor:
Name of Patient: Diagnosis:
Age:                   Sex: Location:
APPENDIX – 8



